Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2017

Mechanisms associated with activation of intracellular
metabotropic glutamate receptor, mGluR5
Yuh-Jiin I. Jong
Washington University School of Medicine in St. Louis

Karen L. O'Malley
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Jong, Yuh-Jiin I. and O'Malley, Karen L., ,"Mechanisms associated with activation of intracellular
metabotropic glutamate receptor, mGluR5." Neurochemical Research. 42,1. 166-172. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5669

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Neurochem Res (2017) 42:166–172
DOI 10.1007/s11064-016-2026-6

ORIGINAL PApER

Mechanisms Associated with Activation of Intracellular
Metabotropic Glutamate Receptor, mGluR5
Yuh-Jiin I. Jong1 · Karen L. O’Malley1

Received: 18 May 2016 / Revised: 18 July 2016 / Accepted: 29 July 2016 / Published online: 11 August 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract The group 1 metabotropic glutamate receptor,
mGluR5, is found on the cell surface as well as on intracellular membranes where it can mediate both overlapping and
unique signaling effects. Previously we have shown that glutamate activates intracellular mGluR5 by entry through sodiumdependent transporters and/or cystine glutamate exchangers.
Calibrated antibody labelling suggests that the glutamate
concentration within neurons is quite high (~10 mM) raising
the question as to whether intracellular mGluR5 is maximally
activated at all times or whether a different ligand might be
responsible for receptor activation. To address this issue, we
used cellular, optical and molecular techniques to show that
intracellular glutamate is largely sequestered in mitochondria;
that the glutamate concentration necessary to activate intracellular mGluR5 is about ten-fold higher than what is necessary
to activate cell surface mGluR5; and uncaging caged glutamate within neurons can directly activate the receptor. Thus
these studies further the concept that glutamate itself serves
as the ligand for intracellular mGluR5.
Keywords Metabotropic · Glutamate · GPCR · Calcium

Introduction
Signal transduction from G protein coupled receptors
(GPCRs) has traditionally been thought to emanate from the
cell surface where many signaling complexes are clustered

Karen L. O’Malley
omalleyk@wustl.edu
1

Department of Neuroscience, Washington University School
of Medicine, 660 South Euclid Ave, Saint Louis,
MO 63110, USA

123

and where extracellular stimuli can interact with GPCR
ligand binding domains. Recently, however, numerous
GPCRs have also been found to be associated with various intracellular membranes where, in certain cases, they
activate intracellular signaling machinery leading to unique
functional responses [1–11]. One such receptor is the
metabotropic glutamate receptor, mGluR5, which is highly
expressed on intracellular membranes including the ER and
nuclear membranes throughout the CNS [12, 13]. Endogenous nuclear mGluR5 couples to Gq and PLC to generate
IP3-mediated Ca2+ release within the nucleus and activation
of intracellular mGluR5 generates unique Ca2+ responses
as well as downstream signaling cascades distinct from cell
surface counterparts, [14, 15]. These observations and those
by others challenge the notion that cells only interact with
their environment at the plasma membrane to bring about
long term changes.
The question arises then as to what ligand activates
intracellular mGluR5 and mechanistically how activation
is achieved. The most parsimonious answer is that as the
natural ligand, glutamate itself may activate intracellular
mGluR5. Glutamate uptake is mediated by at least five
sodium-dependent transporter proteins that are present on
glial and neuronal cells as well as the chloride-dependent
cystine-glutamate exchanger [16–21]. Previous data show
that both of these uptake systems are responsible for transporting glutamate into striatal, hippocampal and/or spinal
cord dorsal horn neurons to activate mGluR5 [13, 22–24].
Conditions that block the transporters (i.e., chloride-free
buffers and the compound l-cystine for the cystine/glutamate exchanger; sodium free buffers and the compound,
threo-β-benzyloxyaspartate for sodium-dependent excitatory amino acid transporters) reduce agonist uptake in
mGluR5-expressing neurons [13, 22–24]. Moreover,
uptake of radiolabeled quisqualate, an mGluR5 agonist, and
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glutamate is also observed in isolated nuclei, which can be
blocked with chloride-free buffers or by applying the same
transporter blockers. Thus, 90–95 % of all ligand-induced
intracellular responses can be accounted for by these ligand
transport processes [13, 22–24].
Besides mechanisms by which glutamate can enter the cell,
another limitation to the notion that endogenous ligand can
activate intracellular mGluR5 is the idea that cytoplasmic glutamate concentrations are in the mM range. Indeed, 10 mM is
frequently used as the concentration of cytoplasmic glutamate
with levels ranging up to 100–200 mM within vesicles [25]. If
cytoplasmic glutamate concentrations are indeed 10 mM then
an intracellular glutamate receptor would be maximally activated or possibly desensitized long before a new bolus of glutamate entered the cell. To address these issues we have used
cellular, optical and molecular techniques to determine the (1)
intracellular localization of glutamate; (2) concentrations necessary to activate cell surface and intracellular mGluR5; and
(3) the effects of uncaging caged glutamate within neurons.

Materials and Methods
Cell Culture and Transfection
Primary cultures of striatal neurons were prepared from postnatal day 1 rat pups as previously described [13]. The cells
were plated onto 12-mm poly-d-lysine-coated glass coverslips (60,000/coverslip) for immunostaining or Ca2+ imaging. Cells were cultured in humidified air with 5 % CO2 at
37 °C for 11–15 days before use. For experiments using the
microplate reader, cultures were plated at 40,000 cells per
well in black-walled, clear-bottomed 96-well plates and then
cultured as above. Striatal cultures were transfected with
plasmid mito-eYFP (gift from Dr. Ian Reynolds; Department
of Pharmacology, University of Pittsburgh, Pittsburgh, Pennsylvania) using lipofectamine 2000 (Invitrogen, Carlsbad,
CA) on DIV 9 and then immunostained on DIV 10.
Immunocytochemistry
Striatal cultures were fixed, blocked, and incubated as
described [13]. Primary antibodies include mouse antiglutamate (1:5000; ImmunoStar, Inc., Hudson, WI) and
goat anti-HSP60 (1:100; Santa Cruz Biotechnology, Santa
Cruz, CA). Secondary antibodies include goat anti-mouse
Cy3 and donkey anti-goat Alexa 488 (1:300, Jackson ImmunoResearch, West Grove, PA).
Fluorescent Measurements of Intracellular Ca2+
DIV 11–15 striatal neurons grown on coverslips were loaded
with Ca2+ fluorophore Oregon Green 488 BAPTA-1 AM,
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imaged and quantitated as described [13, 15, 26]. Glutamate
(Sigma-Aldrich, St. Louis, MO) was added at various concentrations in the presence of D-(-)-2-Amino-5-phosphonopentanoic acid (APV, NMDA receptor antagonist, 100 μM,
Tocris); 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX,
AMPA/Kainate receptor antagonist, 20 μM, Tocris); (2S)2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth9-yl) propanoic acid (LY341495, Group 2/3 mGluR
antagonist, 100 nM, Tocris); and 7-(Hydroxyimino)
cyclopropa[b]chromen-1a-carboxylate ethyl ester (CPCCOEt, mGluR1 antagonist, 20 μM, Tocris) to detect mGluR5
specific Ca2+ responses.
Fluorescence-Based Ca2+ Flux Assay with Microplate
Reader
Primary striatal cultures (Div11–15) plated in 96-well plates
were loaded with 1 μM Fura-2 AM (Molecular Probes) for
30 min at 37 °C and washed with Hanks’ balanced salt solution (HBSS). The cells were then preincubated with APV
(100 μM), CNQX (20 μM), LY341495 (100 nM), CPCCOEt
(20 μM), and the impermeable, nontransported mGluR5
antagonist 3-[(1S)-1-amino-1-carboxy-2-(9H-thioxanthen9-yl)ethyl]cyclobutane-1-carboxylic acid, (LY393053,
20 μM, Eli Lilly, Indianapolis, IN) in HBSS for 20 min at
37 °C prior to measure intracellular mGluR5 specific Ca2+
flux. Fura-2 fluorescence was measured using a BioTek™
Synergy™ H4 Hybrid Microplate Reader (BioTek, Winooski, VT). The baseline 340/380 nm excitation ratio for
fura-2 was collected for 5 s before injecting various concentration of glutamate. Data were collected for an additional
30 s and then analyzed using Biotek’s Gen5 analysis software. The dose-response curves were fit using the GraphPad
Prism 3.0 program (Graphpad Software, San Diego, CA).
Caged Glutamate Experiments
DIV11–15 striatal cultures were loaded with Oregon green
BAPTA-1 AM (Molecular Probes, Eugene, OR) as described
[13]. Cells were microinjected with fluoro-ruby (3.2 mg/
ml, Molecular Probes) and 20 mM 4-Methoxy-7-nitroindolinyl-caged-l-glutamate (MNI-caged-glutamate, Tocris,
Avonmouth, Bristol, United Kingdom) using the single cell
electroporator, Axoporator 800A (Molecular Devises, Silicon
Valley, CA). Alternatively, MNI-caged glutamate was bath
applied to the cells at a concentration of 200 μM. Cells were
kept at 37 °C and imaged on an Olympus FluoView™ FV1000
confocal microscope with a SIM scanner. Photo-uncaging
was performed using 405 nm laser with Tornado scanning
within the region of interest (ROI) for 500 ms. Where indicated, the following antagonists were used at the indicated
concentration: APV (100 μM); CNQX (20 μM); LY341495
(100 nM); CPCCOEt (20 μM), LY393053 (20 μM) and
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2-Methyl-6-(phenylethynyl)pyridine (MPEP, 10 μM, Tocris).
Calcium responses in the ROI and control areas were analyzed using MetaMorph software (Molecular Devises).

Results
Glutamate is Sequestered in Neuronal Mitochondria
Previous studies using techniques such as 13C-NMR,
13
C- and/or 15N-GC/MS have provided compelling evidence
that glutamate has many fates within the cell. For example,
a large proportion of glutamate is taken up by the mitochondria where it is transaminated and serves as a substrate for
the TCA cycle [27, 28]. Indeed, anti-glutamate immunogold
electron microscopy studies indicate that particles representing glutamate are clustered over mitochondria as well
as the nucleus [29]. We have previously shown that mGluR5
is highly expressed in GABA-ergic striatal neurons [13]. To
determine whether glutamate could be visualized in striatal

Fig. 1 Intracellular glutamate pools are predominantly localized in
mitochondria. a Glutamate co-localizes with mitochondrial-targeted
YFP. Cultured striatal neurons were transfected with mito-YFP (green)
and stained with anti-glutamate (red). b Colocalization of glutamate
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neurons, we transfected cultures with mito-YFP to label
mitochondria and then fixed and stained for glutamate. In
support of EM studies showing anti-glutamate immunogold particles over mitochondria [30], immunofluorescence
showed anti-glutamate co-localized with mito-YFP in striatal cell bodies and processes (Fig. 1a). In addition, cultures
stained with HSP60, a marker of mitochondria as well as
anti-glutamate also showed co-localization (Fig. 1b). Thus
the majority of immunoreactive glutamate within these
GABA-ergic neurons is compartmentalized in mitochondria.
“Location” Bias Apparent in Receptor-Mediated
Ca2+ Responses
Earlier studies [15] showed no significant differences in glutamate binding at receptors prepared from striatal plasma
membrane or intracellular membrane sources. Those studies, however, did not address location-specific receptor
responses in terms of function. Therefore, we used real
time Ca2+ imaging to determine half-maximal glutamate

(red) with the mitochondrial marker, HSP60 (green). For a, b magnified images of boxed area in upper panels are shown below (Color
figure online)
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concentrations associated with the plasma membrane or
intracellular mGluR5-mediated Ca2+ responses. As shown
previously [15], glutamate-mediated Ca2+ changes consisted of two phases, an initial rapid rise followed by a sustained elevation (Fig. 2a, red trace). Both sets of responses
were terminated by the addition of the permeable mGluR5
antagonist, MPEP, whereas cultures pretreated with the
impermeable, nontransported antagonist LY393053, only
exhibited a sustained Ca2+ response pattern (not shown). As
shown previously, LY393053 by itself had no effect on Ca2+
responses in striatal cultures [13–15]. In contrast, addition
of the nontransported agonist, DHPG, led to a rapid transient Ca2+ peak (Fig. 2a, blue trace), which could be blocked
by LY393053 (not shown). The half-maximal glutamate
concentration to stimulate a rapid transient Ca2+ response
(cell surface) is 2.21 ± 0.8 μM (Fig. 2b) whereas the halfmaximal concentration to induce a sustained plateau Ca2+
response (intracellular; [15]) is 21.4 ± 4.0 μM (Fig. 2c).
To extend these results, we used a fluorescence-based
2+
Ca flux plate-reader assay in which cells were loaded with
the ratiometric Ca2+ indicator Fura-2 AM before Ca2+ flux
measurement. Previously we used this assay system to show
that mGluR5-expressing spinal cord dorsal horn neurons

couple to PLC to induce release of Ca2+ from intracellular
stores [24]. Here, we used this assay to show that the half
maximal glutamate concentration for intracellular mGluR5
is 61.3 ± 20.3 μM (Fig. 2d). Presumably, the increased EC50
value associated with intracellular mGluR5 reflects properties of the uptake mechanisms involved in glutamate transport into the cell [13, 15]. Collectively, these data show that
intracellular, striatal mGluR5 can function independently
of signals originating at the cell surface and thus plays a
dynamic role in mobilizing Ca2+ in a specific, localized
manner. In addition these data emphasize that intracellular
receptors can be activated with glutamate concentrations far
lower than the putative intracellular cytoplasmic concentration, consistent with the notion that glutamate is sequestered
in the cell.

Fig. 2 Half-maximal glutamate concentrations associated with intracellular mGluR5-mediated Ca2+ responses in striatal neurons. a–c DIV
11–15 striatal neurons grown on coverslips were loaded with Ca2+ fluorophore Oregon Green 488 BAPTA-1 AM and imaged. a Glutamate
dose-dependency in Ca2+ responses; only a single transient peak (blue)
is observed at glutamate doses below 5 μM whereas both transient and
sustained peaks (red) are seen with higher glutamate concentrations. b
The EC50 glutamate concentration to stimulate a rapid transient Ca2+
response (cell surface) is 2.21 ± 0.8 μM. Error bars represent SEM.
(N = 3). c The EC50 glutamate concentration to induce a sustained Ca2+

response (intracellular) is 21.4 ± 4.0 μM, Error bars represent SEM.
(N = 3). d DIV 11–15 striatal neurons plated on 96-well plates were
loaded with fura-2 AM for Ca2+ flux plate reader assay. The baseline
340/380 nm excitation ratio for fura-2 was collected for 5 s before
injecting with various concentrations of glutamate. Data were normalized to a glutamate (2 mM) control maximum. Concentration-response
curves were generated from the mean data of three experiments. Error
bars represent SEM. The EC50 glutamate concentration for intracellular mGluR5 is 61.3 ± 20.3 μM (Color figure online)

Selective Uncaging of Glutamate Activates Intracellular
mGluR5 Within the Cell and in the Dendrites
To further demonstrate that glutamate activates intracellular mGluR5, we electroporated caged glutamate (MNI-Glu)
into individual neurons along with fluoro-ruby to tag recipient cells. Following electroporation, cultures were loaded
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with Oregon Green BAPTA-1 AM and preincubated with
LY393053 as well as ionotropic receptor (NMDA, AMPA,
and kainate receptors), mGluR1, and Groups 2 and 3 mGluR
antagonists prior to uncaging a ROI (Fig. 3a). Only neuronal somas subjected to laser-induced photolysis (uncaging) showed mGluR5-mediated Ca2+ changes (Fig. 3b; red
trace), neuronal somas without uncaging showed no change
in Ca2+ responses (Fig. 3b; blue trace). These data demonstrate that releasing glutamate within the cell can activate
intracellular mGluR5.
Because ultrastructure studies have also shown large
numbers of mGluR5 gold particles on endoplasmic reticulum (ER) membranes [12], we tested whether mGluR5
expressed on dendritic ER or endosomal membranes can
mediate local Ca2+ rises. To do so intracellular receptors
were pharmacologically isolated by blocking cell surface
mGluR5 with LY393053 as well as mGluR1, ionotropic and
Group 2/3 mGluR targets. In addition to the antagonists, the
extracellular buffer also contained MNI-glutamate which
was uncaged in an ROI on a striatal dendrite at least 20 μm
away from the cell body (Fig. 3c). Only the region of the
dendrite juxtaposed to the uncaging spot exhibited a change

in fluorescence whereas the surrounding regions did not
(Fig. 3c, d). MPEP blocked all Ca2+ responses (not shown).
These data emphasize the notion that some of the signaling
originates in the ER, an organelle not easily assayed other
than using the selective tools described here. Thus akin to
results in the hippocampus [23], our findings indicate that
activation of dendritic, intracellular mGluR5 also leads to
in situ Ca2+ changes with neither input to nor output from
the cell soma.

Fig. 3 Regionally selective uncaging of glutamate in the presence of
cell surface inhibitors activates intracellular mGluR5 in striatal soma
(a, b) and dendrites (c, d ). a, b Striatal neurons were injected with
fluoro-ruby and MNI-caged-glutamate. Uncaging of MNI-glutamate
at a somal ROI induced a Ca2+ rise at the red ROI whereas no Ca2+
changes were seen at the blue ROI (N = 5). c, d MNI-caged glutamate
was bath applied to striatal cultures at a concentration of 200 µM.

MNI-glutamate was uncaged on a striatal dendrite at the red ROI in
the presence of LY53 (20 µM), the NMDA receptor blocker APV
(100 µM), the AMPA/Kainate receptor blocker CNQX (20 µM), the
mGluR1 blocker CPCCOEt (20 µM) and the Group 2/3 mGluR antagonist LY341495 (100 nM). Uncaged glutamate generated a Ca2+ rise at
the red ROI whereas no Ca2+ changes were seen in a different neurite
in the same field (white arrows) (N = 10) (Color figure online)
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Discussion
In addition to functioning as a neurotransmitter, glutamate
serves many metabolic roles within the cell such as acting
as a building block for protein synthesis, playing a role in
energy metabolism, and transferring reducing equivalents
from the cytoplasm to the mitochondria [31]. Given these
myriad tasks, it is not surprising that intracellular glutamate
concentrations are thought to be in the mM range. Contrary
to this notion, here we show that glutamate is largely compartmentalized in mitochondria, at least in striatal neurons.
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Moreover, the EC50 for glutamate activation of intracellular
mGluR5 is ~61 μM, a value inconsistent with high concentrations of “free” glutamate within the cytoplasm. Finally
uncaging glutamate within the neuronal soma led to a rapid
mGluR5-mediated Ca2+ response further demonstrating
intracellular glutamate activation of intracellular receptors.
These studies do not rule out the possibility that glutamate could also be generated in situ. For example, glutamate
may also be generated within the nucleus by phosphateactivated l-type glutaminase [32]. Studies by Aledo and
co-workers have shown that throughout the brain of humans,
monkeys, rats and many other species, l-type glutaminase can be found primarily in the nucleus where it exhibits kinetics consistent with those of the better characterized
liver enzyme [32]. More recently, GIP, a scaffolding protein
known to bind to a PDZ domain within l-type glutaminase,
has been shown to be associated with ER and nuclear membranes [33]. Thus, in addition to transport from extracellular
sources and in situ cytoplasmic production, enzymes and
scaffolding proteins exist to localize glutamate production
near intracellular mGluR5.
In conclusion, uncertainties regarding the concentrations, fate and function of intracellular glutamate as well
as findings showing the highly compartmentalized nature of
glutamate production and disposition have obscured studies
on intracellular receptors and transporters such as mGluR1
[22], mGluR5, and EAAT3. These uncertainties have
delayed progress in discerning the role of intracellular glutamate as well as the functional consequences of its production and/or uptake. For instance, the presence of EAAT3 on
postsynaptic processes as well as intracellular membranes
suggests that glutamate could be targeted to other receptors/channels that might also be present on intracellular
membranes. Because these transporters work in “reverse”,
glutamate could bind to any ligand binding domain present
on the same membrane as a given transporter. Given that
such proteins would still maintain their “signaling” domains
within the cytoplasm, entirely new signaling molecules
might be associated with these intracellular receptors. Akin
to β-arrestin-scaffolded GPCRs, one set of second messenger systems might be exchanged for another [34]. In support of this notion, our data show that activated intracellular
receptors generate sustained Ca2+ responses and trigger
completely different signaling pathways [15]. As mGluR5
plays important roles in development, synaptic function, and
learning and memory as well as pathological roles in Fragile X syndrome, anxiety, addiction, and Parkinson disease,
understanding the long term consequences of intracellular
receptor activation might lead to novel therapeutic strategies for these disorders. It seems likely that besides receptorspecific characteristics and signaling partners that the many
factors that modulate glutamate metabolism such as transporter distribution, fluctuation of metabolite concentration,
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and regulation of the many enzymes involved in its production will also play an important role in receptor activation.
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